Mobia Medical earnings release, August 11, 2026

Mobia Medical, Inc. (MOBI) · Form 8-K, Item 2.02 · Filed · SEC filing

Mobia Medical Reports Second Quarter 2026 Financial Results

Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended June 30, 2026.

Second Quarter 2026 and Recent Highlights

• Reported revenue of $13.5 million, representing 102% growth over the prior year period

• Achieved gross margin of 83.2%

• Announced publication of two-year VNS-REHAB follow up data in

Neurology®, demonstrating durable and clinically meaningful improvement in upper-limb motor function, activities of daily living, and quality of life

• Completed initial public offering, raising approximately $134.0 million in net proceeds

• Appointed Myriam Curet, M.D. and Reza Zadno, Ph.D. to the Board of Directors, adding strategic medtech operating experience and clinical leadership

“We delivered a strong second quarter, with revenue more than doubling year-over-year, reflecting consistent growth and increased momentum in our commercial organization,” said Richard Foust, President and CEO of Mobia Medical. “Following the completion of our IPO, we are well positioned to continue broadening our footprint and accelerating patient access to Vivistim® Paired VNS™ Therapy. We are committed to redefining what recovery looks like for millions of ischemic stroke survivors who are living with chronic upper extremity impairment, and we are still in the early stages of addressing this profound unmet clinical need.”

Second Quarter 2026 Financial Results

Revenue increased by 102%, to $13.5 million for the second quarter of 2026, compared to $6.7 million for the second quarter of 2025. The increase was driven primarily by higher adoption of the Vivistim System and an increased number of IPG units sold.

Gross profit increased by 105%, to $11.2 million for the second quarter of 2026, compared to $5.5 million for the second quarter of 2025. Gross margin was 83.2% for the second quarter of 2026, compared to 82.3% for the second quarter of 2025. The increase was primarily due to freight and tariff costs recognized in cost of goods sold during the period, partially offset by other changes in product and warranty costs.

Operating expenses increased 83% to $29.2 million for the second quarter of 2026, compared to $16.0 million for the second quarter of 2025. The increase was primarily due to higher personnel and commission expenses in the commercial organization to support the Company’s growth, as well as increased development costs and general and administrative expenses.

Net loss was $21.0 million, or $1.10 per share for the second quarter of 2026, compared to a net loss of $10.5 million, or $12.44 per share for the second quarter of 2025. The year-over-year decrease in net loss per share primarily reflects the significant increase in weighted-average common shares outstanding following the

Company’s IPO and the related conversion of its outstanding redeemable convertible preferred stock and convertible notes into common stock.

As of June 30, 2026, cash and cash equivalents totaled $177.1 million. The Company received approximately $134.0 million of net proceeds from its initial public offering, which closed in May 2026, after deducting the underwriters’ discounts and commissions, and offering costs.

2026 Outlook

The Company expects revenue for the full year 2026 to be in the range of $54.0 million to $56.0 million, representing growth of 69% to 75% over the full year 2025.

Conference Call and Webcast Details

The Company will host a conference call today, August 11, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2026 financial results. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast can also be accessed via the

News & Events page of the investor section of Mobia Medical’s website.

About Mobia Medical, Inc.

Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended — (in thousands, except share and per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Revenue13,5056,67425,57912,335
Cost of goods sold2,2671,1844,4002,199
Gross profit11,2385,49021,17910,136
Operating expensesResearch and development costs2,2781,4183,9702,772
Operating expensesSelling, general and administrative expenses26,88614,53252,07228,128
Operating expensesTotal operating expenses29,16415,95056,04230,900
Operating expensesLoss from operations-17,926-10,460-34,863-20,764
Other income (expense)Change in fair value of convertible notes payable-4,142-4,870
Other income (expense)Interest expense-254-241-611-480
Other income (expense)Other income (expense), net1,2812131,563104
Other income (expense)Total other expense, net-3,115-28-3,918-376
Other income (expense)Loss before provision for income tax-21,041-10,488-38,781-21,140
Other income (expense)Provision for income tax-2-2-2-3
Other income (expense)Net loss attributable to common stockholders-21,043-10,490-38,783-21,143
Net loss per share attributable to common stockholdersBasic-1.1-12.44-3.86-25.41
Net loss per share attributable to common stockholdersDiluted-1.1-12.44-3.86-25.41
Weighted average shares used to compute net loss per share attributable to common stockholdersBasic19,089,211843,16810,054,267832,224
Weighted average shares used to compute net loss per share attributable to common stockholdersDiluted19,089,211843,16810,054,267832,224

Balance Sheet

December 31, — (in thousands, except share and per share data)

June 30, – 2026December 31, – 2025
Current assetsCash and cash equivalents177,09033,587
Current assetsAccounts receivable5,6644,435
Current assetsInventory6,9495,457
Current assetsDeferred offering costs935
Current assetsOther current assets2,4461,943
Current assetsTotal current assets192,14946,357
Current assetsProperty and equipment, net2,060669
Current assetsRight-of-use assets — operating leases9321,068
Current assetsOther assets14355
Current assetsTotal assets195,28448,149
Current liabilitiesAccounts payable2,3592,223
Current liabilitiesOperating lease liabilities, current358358
Current liabilitiesProduct warranty liability1,263844
Current liabilitiesAccrued payroll, commissions, and bonuses4,9974,854
Current liabilitiesAccrued offering costs3,500935
Current liabilitiesAccrued and other current liabilities1,995992
Current liabilitiesTotal current liabilities14,47210,206
Current liabilitiesWarrant liabilities134865
Current liabilitiesNotes payable, net of discount and deferred financing costs7,2797,130
Current liabilitiesOperating lease liabilities, non-current790948
Current liabilitiesTotal liabilities22,67519,149
Current liabilitiesRedeemable convertible preferred stock179,773
Stockholders’ equity (deficit)Common stock3339
Stockholders’ equity (deficit)Additional paid-in capital368,8487,007
Stockholders’ equity (deficit)Accumulated deficit-196,572-157,789
Stockholders’ equity (deficit)Total stockholders’ equity (deficit)172,609-150,773
Stockholders’ equity (deficit)Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)195,28448,149
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Mobia Medical’s full year 2026 revenue guidance and the assumptions underlying that guidance and Mobia Medical’s plans to broaden its commercial reach and accelerate patient access to the Vivistim System. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”

... (truncated) include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future, which are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied. These risks and uncertainties include, among others, those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in Mobia Medical’s filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release, and Mobia Medical undertakes no obligation to update or revise any forward-looking statements except as required under applicable law. Mobia Medical may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Investor Relations Contact

Louisa Smith

Gilmartin Group, LLC investors@mobia.com

Media Inquiries Contact

Terri Clevenger tclevenger@waterhousebrands.com

Mobia Medical, Inc.

Conden sed Balance Sheets

(Unaudited)

(in thousands, except share and per share data)

Mobia Medical, Inc.

Conde nsed Statements of Operations

(Unaudited)

(in thousands, except share and per share data)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Mobia Medical earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.